In Vitro and In Vivo Investigation of a Dual-Targeted Nanoemulsion Gel for the Amelioration of Psoriasis
in-vitro Grade C 2023 Open access
Authors: Khan, R., Mirza, M.A., Aqil, M., Alex, T.S., Raj, N., Manzoor, N., Naseef, P.P., Kuruniyan, M.S., Iqbal, Z.
Journal: Gels 9 (2) : 112
DOI: 10.3390/gels9020112
Key Findings
- Nanoemulsion gel combining Thymoquinone (TQ) and Fulvic Acid (FA) developed for psoriasis treatment
- Molecular docking showed TQ and FA binding to IL-6 (4CNI) and TNF-α (6RMJ) targets
- FA incorporated at 100 mg/cm² in gel formulation as one of six treatment groups
- IMQ-induced psoriasis model in BALB/c mice — FA+TQ nanoemulsion reduced ear thickness, erythema, scaling
- PASI scoring system used: 0-4 scale for erythema, scaling, lesions, thickness
- TQ suppresses epidermal proliferation and differentiation via inhibiting dendritic cells and IL-6/TNF-α generation
Combined in vitro and in vivo study developing a dual-targeted nanoemulsion gel (NEG) containing Thymoquinone (from Nigella sativa) and Fulvic Acid for psoriasis treatment. In silico molecular docking confirmed FA binding to IL-6 and TNF-α protein targets. In vivo testing used IMQ-induced psoriasis in BALB/c mice across 6 groups including FA-only gel. Results demonstrated reduced inflammation markers. Study is notable for being one of the first to use FA specifically in a psoriasis formulation context, though the combined TQ+FA formulation makes it difficult to isolate FA’s independent contribution.
fulvic-acidthymoquinonepsoriasisnanoemulsiongelin-vivomouse-modelIL-6TNF-alpha